Table 3.
Persistent symptoms at follow-up in relevant interstitial lung sequelae (RILS) groups classified by the Warrick score.
| Non-RILS group (n = 198) | RILS group (n = 154) | Total (N = 352) | *P-value | |
|---|---|---|---|---|
| Persistent symptoms, n (%) | ||||
| Any symptoms | 126 (63.6) | 118 (76.6) | 244 (69.3) | 0.010 |
| Dyspnea mMRC score = 0 | 121 (61.1) | 61 (39.6) | 182 (51.7) | <0.001 |
| Dyspnea mMRC score ≥ 1 | 77 (38.9) | 93 (60.4) | 170 (48.3) | |
| Cough | 34 (17.2) | 23 (14.9) | 57 (16.2) | 0.558 |
| Expectoration | 5 (2.5) | 0 (0) | 5 (1.4) | 0.071 |
| Chest pain | 22 (11.1) | 15 (9.7) | 37 (10.5) | 0.677 |
| Fatigue or muscle weakness | 64 (32.3) | 65 (42.2) | 129 (36.6) | 0.056 |
| Myalgia or arthralgia | 44 (22.2) | 41 (26.6) | 85 (24.1) | 0.339 |
| Headache | 13 (6.6) | 4 (2.6) | 17 (4.8) | 0.085 |
| Sleep difficulties | 9 (4.5) | 3 (1.9) | 12 (3.4) | 0.186 |
| Fever | 0 (0.0) | 3 (1.9) | 3 (0.9) | 0.083 |
| Digestive symptoms | 4 (2.0) | 2 (1.3) | 6 (1.7) | 0.699 |
| Taste or smell disorder | 8 (4.0) | 7 (4.5) | 15 (4.3) | 0.816 |
*
P-value comparisons between non-RILS and RILS groups.
RILS, relevant interstitial lung sequelae, defined by a Warrick score ≥ 7.
IQR, interquartile range; MMRC, modified medical research council; RILS, relevant interstitial lung sequelae.